{
  "context": {
    "rules": [
      "Rule1: In the event that the epidemiologist identifies the outbreak source, treatment z cures disease d.",
      "Rule2: Provided that the microbiologist isolates the pathogen strain, treatment z cures disease d.",
      "Rule3: Either the assistant mislabels chemical x, or, alternatively, either the epidemiologist identifies the outbreak source or the microbiologist isolates the pathogen strain.",
      "Rule4: Whenever the supervisor corrects the mislabeling, it is not the case that the assistant mislabels chemical x.",
      "Rule5: Under the condition that the journal investigates paper beta, the reviewer confirms the findings.",
      "Rule6: If the journal investigates paper beta, then the statistician questions the methodology.",
      "Rule7: In the scenario where the journal investigates paper beta, the editor requests a revision.",
      "Rule8: Given that the reviewer confirms the findings, the study team does not plagiarize paper gamma.",
      "Rule9: The FDA authorizing treatment z is sufficient for the FDA regulating treatment z.",
      "Rule10: The FDA issuing a safety alert is a condition for the FDA recalling treatment z.",
      "Rule11: If the statistician reanalyzes the data, then, provided that the statistician questions the methodology, the study team does not plagiarize paper gamma.",
      "Rule12: The independent lab replicates the experiment, or the replication attempt fails the experiment.",
      "Rule13: If the replication attempt fails the experiment, then, assuming that (neither the study team publishes paper beta nor treatment z is effective) implies the study team does not plagiarize paper gamma, the consortium does not validate the results.",
      "Rule14: Either the meta-analysis corroborates the findings, or, if it is not the case that the independent lab replicating the experiment implies that (neither the study team publishes paper beta nor treatment z is effective) implies the study team does not plagiarize paper gamma, which then implies the consortium does not validate the results, then the author does not dispute the replication.",
      "Rule15: Chemical x contaminating the sample set implies that, if neither the study team publishes paper alpha nor treatment z is effective, then the editor retracts paper alpha.",
      "Rule16: The peer reviewer finding a flaw in the analysis guarantees that the study team does not plagiarize paper gamma.",
      "Rule17: Whenever the author resubmits the revised paper, the journal accepts it.",
      "Rule18: It is the case that either the author resubmits the revised paper, or the journal rejects the revised paper.",
      "Rule19: Should the journal reject the revised paper, then, if the editor requests a revision, the peer reviewer finds a flaw in the analysis.",
      "Rule20: Either the lab technician sterilizes the equipment, or chemical x contaminates the sample set.",
      "Rule21: The principal investigator violates the protocol, or the principal investigator reports the violation.",
      "Rule22: If the principal investigator reports the violation, then either the ethics board approves the protocol or the lab technician does not sterilize the equipment.",
      "Rule23: Treatment z curing disease d is sufficient for treatment z to be effective.",
      "Rule24: In the event that neither the study team publishes paper alpha nor treatment z is effective, the editor does not retract paper alpha.",
      "Rule25: Provided that neither the study team publishes paper beta nor treatment z is effective, the study team plagiarizes paper gamma.",
      "Rule26: Under the condition that neither the study team publishes paper beta nor treatment z is effective, the journal investigates paper beta.",
      "Rule27: When it is not the case that the FDA fast tracking treatment z implies the FDA authorizing treatment z, the FDA issues a safety alert.",
      "Rule28: In the scenario where it is not the case that the FDA fast tracking treatment z implies the FDA authorizing treatment z, the FDA does not recall treatment z.",
      "Rule29: If it is not the case that the independent lab replicating the experiment implies that (neither the study team publishes paper beta nor treatment z is effective) implies the study team does not plagiarize paper gamma, which then implies the consortium does not validate the results, then the author disputes the replication.",
      "Rule30: If it is not the case that the principal investigator violating the protocol implies that either the ethics board approves the protocol or the lab technician does not sterilize the equipment, then the funding body suspends the grant.",
      "Rule31: Assuming that (neither the study team publishes paper beta nor treatment z is effective) implies the study team does not plagiarize paper gamma, then the consortium validates the results.",
      "Rule32: Whenever treatment z is not effective, the FDA fast tracks treatment z."
    ],
    "facts": [
      "Fact1: The supervisor corrects the mislabeling.",
      "Fact2: The statistician reanalyzes the data.",
      "Fact3: It is not the case that the study team publishes paper alpha.",
      "Fact4: The study team does not publish paper beta.",
      "Fact5: The FDA does not regulate treatment z.",
      "Fact6: The meta-analysis does not corroborate the findings.",
      "Fact7: The journal does not accept the revised paper.",
      "Fact8: The ethics board does not approve the protocol.",
      "Fact9: The funding body does not suspend the grant."
    ]
  },
  "question": "Treatment z is effective."
}